Unknown

Dataset Information

0

Tumour neoantigen heterogeneity thresholds provide a time window for combination immunotherapy.


ABSTRACT: Following the advent of cancer immunotherapy, increasing insight has been gained on the role of mutational load and neoantigens as key ingredients in T cell recognition of malignancies. However, not all highly mutational tumours react to immune therapies, and initial success is often followed by eventual relapse. Heterogeneity in the neoantigen landscape of a tumour might be key in the failure of immune surveillance. In this work, we present a mathematical framework to describe how neoantigen distributions shape the immune response. The model predicts the existence of an antigen diversity threshold level beyond which T cells fail at controlling heterogeneous tumours. Incorporating this diversity marker adds predictive value to antigen load for two cohorts of anti-CTLA-4 treated melanoma patients. Furthermore, our analytical approach indicates rapid increases in epitope heterogeneity in early malignancy growth following immune escape. We propose a combination therapy scheme that takes advantage of preexisting resistance to a targeted agent. The model indicates that the selective sweep for a resistant subclone reduces neoantigen heterogeneity, and we postulate the existence of a time window before tumour relapse where checkpoint blockade immunotherapy can become more effective.

SUBMITTER: Aguade-Gorgorio G 

PROVIDER: S-EPMC7653380 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6137806 | biostudies-literature
| S-EPMC4971382 | biostudies-literature
| S-EPMC7080439 | biostudies-literature
| S-EPMC8654996 | biostudies-literature
| S-EPMC6021135 | biostudies-literature
| S-EPMC6036114 | biostudies-literature
| S-EPMC8085349 | biostudies-literature
| S-EPMC5601925 | biostudies-literature
2021-11-17 | GSE188582 | GEO
| S-SCDT-10_15252-EMMM_202216836 | biostudies-other